Aktuellt
SENASTE
Redeye revisits its view of Alzecure in the wake of the company’s pipeline progress and recent rights issue. We continue to see an interesting neurology platform case with an exiting year ahead. We argue that the company’s current valuation is undemanding and see a solid entry point at these levels.
LÄS MER
